Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer

Table 2

Comparison of treatment efficacy of patients in the four groups (n (%)).

Groups	n	Markedly effective	Effective	Ineffective	Deteriorated	Total efficacy
Control group	51	4	13	27	7	33.33%
Study group I	51	8	22	18	2	58.82%^a
Study group II	51	10	25	15	1	68.63%^a
Study group III	51	6	19	23	3	49.02%^a
X^2						15.259
						0.002

^aStatistically significant difference in comparison with the control group.